Beta-cell Response to Incretin Hormones in Cystic Fibrosis
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
In recent years, diabetes has emerged as one of the most significant co-diseases that many
Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when
either the body does not make enough insulin or the body does not respond correctly to this
insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps
carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic
fibrosis related diabetes (CFRD) has many features similar to both T1D and T2D, patients with
CF may not have the same symptoms as either T1D or T2D patients. Currently, there is little
understanding of CFRD and the best options for treatment remain unclear.
The purpose of this research study is to examine and understand the various mechanisms that
contribute to CFRD and gain a better understanding of potential means to treat CFRD. In
particular, we plan to study the effects of incretin hormones that can enhance insulin
production in CF patients.
Enrollment is complete for the protocol as initially written. In order to further study the
role of the incretin hormone on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
function , we have received approval to extend our investigation to include the following
study groups:
- Cystic Fibrosis participants with normal glucose tolerance
- Non-Cystic Fibrosis controls